About Us
Myriad Pharmaceuticals, Inc. is a fully integrated biotechnology company discovering, developing and commercializing first-in-class/best-in-class products for the treatment of diseases with high unmet need such as cancer and HIV infection. Our pipeline includes clinical and pre-clinical product candidates with distinct mechanisms of action and novel chemical structures that have the potential to be first-in-class and/or best-in-class therapeutics.
The discovery and development of each of our drug candidates has been guided by a unique understanding of the genetic causes of human diseases, the genetic factors that may cause drug side effects, drug interactions, and poor drug metabolism. Our extensive experience in human genetics, protein-protein interaction technology and chemical proteomic drug discovery has allowed identification of novel drug targets and accelerated progression from chemical lead compounds to investigational drug candidates.
Our corporate strategy:
- Focus resources on three lead clinical drug programs
- Expand preclinical pipeline of drug candidates
- Direct discovery programs to address significant unmet needs in oncology
- Partner to maximize the value of our portfolio
- Accelerate time to market through potential in-licensing or acquisition
To learn more about Myriad Pharmaceuticals, contact us.
